Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short term Debt (2016 - 2025)

Historic Short term Debt for Coherus Oncology (CHRS) over the last 9 years, with Q1 2025 value amounting to $26.2 million.

  • Coherus Oncology's Short term Debt changed N/A to $26.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $26.2 million, marking a year-over-year change of. This contributed to the annual value of $13.6 million for FY2024, which is 31272.73% up from last year.
  • As of Q1 2025, Coherus Oncology's Short term Debt stood at $26.2 million.
  • In the past 5 years, Coherus Oncology's Short term Debt ranged from a high of $26.2 million in Q1 2025 and a low of $90000.0 during Q2 2023
  • Its 4-year average for Short term Debt is $9.5 million, with a median of $9.2 million in 2024.
  • Examining YoY changes over the last 5 years, Coherus Oncology's Short term Debt showed a top increase of 1012444.44% in 2024 and a maximum decrease of 12777.23% in 2024.
  • Coherus Oncology's Short term Debt (Quarter) stood at $17.3 million in 2021, then crashed by 80.93% to $3.3 million in 2023, then soared by 312.73% to $13.6 million in 2024, then soared by 92.57% to $26.2 million in 2025.
  • Its Short term Debt stands at $26.2 million for Q1 2025, versus $13.6 million for Q4 2024 and $9.2 million for Q3 2024.